Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short-Term Debt issuances (2020 - 2022)

Historic Short-Term Debt issuances for Guided Therapeutics (GTHP) over the last 3 years, with Q1 2022 value amounting to -$90000.0.

  • Guided Therapeutics' Short-Term Debt issuances rose 8384.2% to -$90000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was -$842000.0, marking a year-over-year change of. This contributed to the annual value of -$1.5 million for FY2021, which is 3333.33% down from last year.
  • Per Guided Therapeutics' latest filing, its Short-Term Debt issuances stood at -$90000.0 for Q1 2022, which was up 8384.2% from -$53000.0 recorded in Q4 2021.
  • In the past 5 years, Guided Therapeutics' Short-Term Debt issuances ranged from a high of -$53000.0 in Q4 2021 and a low of -$557000.0 during Q1 2021
  • For the 3-year period, Guided Therapeutics' Short-Term Debt issuances averaged around -$210500.0, with its median value being -$116000.0 (2020).
  • In the last 5 years, Guided Therapeutics' Short-Term Debt issuances skyrocketed by 6267.61% in 2021 and then skyrocketed by 8384.2% in 2022.
  • Over the past 3 years, Guided Therapeutics' Short-Term Debt issuances (Quarter) stood at -$142000.0 in 2020, then surged by 62.68% to -$53000.0 in 2021, then tumbled by 69.81% to -$90000.0 in 2022.
  • Its Short-Term Debt issuances was -$90000.0 in Q1 2022, compared to -$53000.0 in Q4 2021 and -$557000.0 in Q1 2021.